Body

Treatment she can plan on.

In RAPID-axSpA, 57% of CIMZIA 200 mg Q2W-treated patients (n=65) vs. 37% of placebo-treated patients (n=57) achieved ASAS20 at week 12.1

 
For AS patients

CIMZIA® (certolizumab pegol) is indicated for the treatment of adult patients with active ankylosing spondylitis (AS).

NEXT: CIMZIA Design
AS